Drug-induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis

被引：4

作者：

Tani, Nozomi ^{[1
]}

Kunimatsu, Yusuke ^{[1
]}

Sato, Izumi ^{[1
]}

Ogura, Yuri ^{[1
]}

Hirose, Kazuki ^{[1
]}

Takeda, Takayuki ^{[1
]}

机构：

[1] Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto, Japan

来源：

RESPIROLOGY CASE REPORTS | 2020年 / 8卷 / 07期

关键词：

Chronic myeloid leukaemia; dasatinib; drug-induced interstitial lung disease; tuberculosis; tyrosine kinase inhibitor; LEUKEMIA;

D O I：

10.1002/rcr2.654

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

A 69-year-old woman was diagnosed with a breakpoint cluster region-Abelson-positive chronic myeloid leukaemia and treated with dasatinib for 14 months. She presented with one month of high-grade fever and persistent dry cough. Chest computed tomography revealed non-segmental subpleural consolidation, ground-glass opacities, and interlobular septal thickening. The bronchoalveolar lavage (BAL) and transbronchial lung biopsy confirmed a diagnosis of drug-induced interstitial lung disease (ILD) associated with dasatinib. Then, systemic corticosteroid treatment was initiated, which was effective and the interstitial shadow disappeared after two weeks. The acid-fast bacilli culture test of BAL fluid after three weeks was positive forMycobacterium tuberculosis, and combination therapy with four antituberculosis drugs was added. It is known that drug-induced ILD and susceptibility to infection associated with dasatinib occur in a dose-dependent manner. This is the first case of dasatinib-induced ILD which coincided with active tuberculosis.

引用

页数：3